179 related articles for article (PubMed ID: 37914923)
1. Impact on Survival of Early Versus Late Initiation of Adjuvant Chemotherapy After Pancreatic Adenocarcinoma Surgery: A Target Trial Emulation.
Kirkegård J; Ladekarl M; Lund A; Mortensen F
Ann Surg Oncol; 2024 Feb; 31(2):1310-1318. PubMed ID: 37914923
[TBL] [Abstract][Full Text] [Related]
2. Effect of adjuvant chemotherapy after pancreatectomy in patients with node-negative pancreatic cancer: target trial emulation.
Kirkegård J; Ladekarl M; Johannsen IR; Mortensen F
Br J Surg; 2024 Jan; 111(1):. PubMed ID: 38006324
[TBL] [Abstract][Full Text] [Related]
3. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.
Reni M; Balzano G; Zanon S; Zerbi A; Rimassa L; Castoldi R; Pinelli D; Mosconi S; Doglioni C; Chiaravalli M; Pircher C; Arcidiacono PG; Torri V; Maggiora P; Ceraulo D; Falconi M; Gianni L
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):413-423. PubMed ID: 29625841
[TBL] [Abstract][Full Text] [Related]
6. Effect of surgery versus chemotherapy in pancreatic cancer patients: a target trial emulation.
Kirkegård J; Gaber C; Heide-Jørgensen U; Fristrup CW; Lund JL; Cronin-Fenton D; Mortensen FV
J Natl Cancer Inst; 2024 Feb; ():. PubMed ID: 38310365
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
[TBL] [Abstract][Full Text] [Related]
8. Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma.
Nussbaum DP; Adam MA; Youngwirth LM; Ganapathi AM; Roman SA; Tyler DS; Sosa JA; Blazer DG
Ann Surg Oncol; 2016 Mar; 23(3):1026-33. PubMed ID: 26542590
[TBL] [Abstract][Full Text] [Related]
9. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Valle JW; Palmer D; Jackson R; Cox T; Neoptolemos JP; Ghaneh P; Rawcliffe CL; Bassi C; Stocken DD; Cunningham D; O'Reilly D; Goldstein D; Robinson BA; Karapetis C; Scarfe A; Lacaine F; Sand J; Izbicki JR; Mayerle J; Dervenis C; Oláh A; Butturini G; Lind PA; Middleton MR; Anthoney A; Sumpter K; Carter R; Büchler MW
J Clin Oncol; 2014 Feb; 32(6):504-12. PubMed ID: 24419109
[TBL] [Abstract][Full Text] [Related]
10. Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival.
Altman AM; Wirth K; Marmor S; Lou E; Chang K; Hui JYC; Tuttle TM; Jensen EH; Denbo JW
Ann Surg Oncol; 2019 Nov; 26(12):4108-4116. PubMed ID: 31313044
[TBL] [Abstract][Full Text] [Related]
11. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
12. Combined-modality treatment for operable pancreatic adenocarcinoma.
Pisters PW; Wolff RA; Crane CH; Evans DB
Oncology (Williston Park); 2005 Mar; 19(3):393-404, 409; discussion 409-10, 412-6. PubMed ID: 15828554
[TBL] [Abstract][Full Text] [Related]
13. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan Pancreas Society.
Tomimaru Y; Eguchi H; Shimomura Y; Kitamura T; Inoue Y; Nagakawa Y; Ohba A; Onoe S; Unno M; Hashimoto D; Kawakatsu S; Hayashi T; Higuchi R; Kitagawa H; Uemura K; Kimura Y; Satoi S; Takeyama Y;
J Gastroenterol; 2023 Aug; 58(8):790-799. PubMed ID: 37329351
[TBL] [Abstract][Full Text] [Related]
14. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
15. Real-world patterns of adjuvant chemotherapy treatment for patients with resected pancreatic adenocarcinoma.
Abdel-Rahman O; Spratlin J; Koski S
Med Oncol; 2021 Feb; 38(2):18. PubMed ID: 33534008
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
Sohal DPS; Duong M; Ahmad SA; Gandhi NS; Beg MS; Wang-Gillam A; Wade JL; Chiorean EG; Guthrie KA; Lowy AM; Philip PA; Hochster HS
JAMA Oncol; 2021 Mar; 7(3):421-427. PubMed ID: 33475684
[TBL] [Abstract][Full Text] [Related]
17. Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemotherapy in Localized Pancreatic Cancer.
Bergquist JR; Ivanics T; Shubert CR; Habermann EB; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB; Truty MJ
Ann Surg Oncol; 2017 Jun; 24(6):1731-1738. PubMed ID: 28070725
[TBL] [Abstract][Full Text] [Related]
18. Time to Initiation of Adjuvant Chemotherapy in Pancreas Cancer: A Multi-Institutional Experience.
Xia BT; Ahmad SA; Al Humaidi AH; Hanseman DJ; Ethun CG; Maithel SK; Kooby DA; Salem A; Cho CS; Weber SM; Stocker SJ; Talamonti MS; Bentrem DJ; Abbott DE
Ann Surg Oncol; 2017 Sep; 24(9):2770-2776. PubMed ID: 28600732
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
Labori KJ; Lassen K; Hoem D; Grønbech JE; Søreide JA; Mortensen K; Smaaland R; Sorbye H; Verbeke C; Dueland S
BMC Surg; 2017 Aug; 17(1):94. PubMed ID: 28841916
[TBL] [Abstract][Full Text] [Related]
20. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Regine WF; Winter KA; Abrams R; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Rich TA; Willett CG
Ann Surg Oncol; 2011 May; 18(5):1319-26. PubMed ID: 21499862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
